secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viatris Inc (VTRS)
CIK:        0001792044
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001792044-23-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viatris reports strong Q2 2023: revenue $3.92B, net income $264M, reaffirms guidance
--------------------------------------------------------------------------------

- Total revenues $3.92B, U.S. GAAP net earnings $264M, adjusted EBITDA $1.31B, free cash flow $447M.
- Reaffirms full-year 2023 total revenues, adjusted EBITDA and free cash flow expected at midpoint of guidance ranges.
- Board declared $0.12/share dividend, payable Sept 15, record Aug 24 (unchanged from prior).
- Paid down $727M debt YTD; on track to announce planned divestitures in 2023, with at least one significant in Q3.
- Launched Breyna (generic Symbicort) in July; new product revenue target on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792044/000179204423000021/0001792044-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792044/000179204423000021/vtrs-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001792044-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer